JP2023509675A - 胃腸障害を治療するための経口用固形カンナビノイド油組成物 - Google Patents

胃腸障害を治療するための経口用固形カンナビノイド油組成物 Download PDF

Info

Publication number
JP2023509675A
JP2023509675A JP2022540709A JP2022540709A JP2023509675A JP 2023509675 A JP2023509675 A JP 2023509675A JP 2022540709 A JP2022540709 A JP 2022540709A JP 2022540709 A JP2022540709 A JP 2022540709A JP 2023509675 A JP2023509675 A JP 2023509675A
Authority
JP
Japan
Prior art keywords
cannabinoid oil
oil
cannabinoid
microcrystalline cellulose
individual particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509675A5 (https=
Inventor
サイド， エム シャー，
フレッド ハッサン，
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2023509675A publication Critical patent/JP2023509675A/ja
Publication of JP2023509675A5 publication Critical patent/JP2023509675A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022540709A 2020-01-08 2021-01-08 胃腸障害を治療するための経口用固形カンナビノイド油組成物 Pending JP2023509675A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958392P 2020-01-08 2020-01-08
US62/958,392 2020-01-08
PCT/EP2021/050245 WO2021140183A1 (en) 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
JP2023509675A true JP2023509675A (ja) 2023-03-09
JP2023509675A5 JP2023509675A5 (https=) 2024-01-16

Family

ID=74236138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540709A Pending JP2023509675A (ja) 2020-01-08 2021-01-08 胃腸障害を治療するための経口用固形カンナビノイド油組成物

Country Status (8)

Country Link
US (2) US12186281B2 (https=)
EP (1) EP4087547A1 (https=)
JP (1) JP2023509675A (https=)
CN (1) CN114845705A (https=)
AU (1) AU2021206021A1 (https=)
BR (1) BR112022010335A2 (https=)
CA (1) CA3164489A1 (https=)
WO (1) WO2021140183A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021417405A1 (en) * 2021-01-08 2023-06-22 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating central nervous system disorders
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017325A1 (en) * 2011-02-11 2014-01-16 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2014505102A (ja) * 2011-02-11 2014-02-27 ズィーエックス ファーマ，エルエルシー 多粒子ｌ−メントール製剤及びその関連する方法
JP2015534582A (ja) * 2013-04-23 2015-12-03 ズィーエックス ファーマ，エルエルシー 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
JP2019510060A (ja) * 2016-03-28 2019-04-11 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ 胃腸管の炎症性疾患の治療のためのカンナビノイドおよびカンナビスベースの組成物および方法
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
JP2019530717A (ja) * 2016-10-12 2019-10-24 コロンビア ケア エルエルシー 抽出されたカンナビノイドの経口組成物およびその使用の方法
WO2019234743A1 (en) * 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
JP2020536873A (ja) * 2017-10-05 2020-12-17 レセプター・ホールディングス・インコーポレイテッド 迅速発現作用延長型の植物系及び合成カンナビノイド製剤
JP2022534763A (ja) * 2019-05-31 2022-08-03 ジーダブリュー・リサーチ・リミテッド カンナビノイド製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
AU2017216928B2 (en) 2016-02-11 2018-09-20 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
WO2017193072A1 (en) 2016-05-06 2017-11-09 Harvest Direct Enterprises Llc The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
MX382609B (es) * 2016-07-25 2025-03-13 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CA3036585A1 (en) 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140017325A1 (en) * 2011-02-11 2014-01-16 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2014505102A (ja) * 2011-02-11 2014-02-27 ズィーエックス ファーマ，エルエルシー 多粒子ｌ−メントール製剤及びその関連する方法
JP2015534582A (ja) * 2013-04-23 2015-12-03 ズィーエックス ファーマ，エルエルシー 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
JP2016517867A (ja) * 2013-04-23 2016-06-20 ズィーエックス ファーマ，エルエルシー タンパク質性サブコートを有する腸溶性の多微粒子組成物
JP2019510060A (ja) * 2016-03-28 2019-04-11 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ 胃腸管の炎症性疾患の治療のためのカンナビノイドおよびカンナビスベースの組成物および方法
JP2019530717A (ja) * 2016-10-12 2019-10-24 コロンビア ケア エルエルシー 抽出されたカンナビノイドの経口組成物およびその使用の方法
JP2020536873A (ja) * 2017-10-05 2020-12-17 レセプター・ホールディングス・インコーポレイテッド 迅速発現作用延長型の植物系及び合成カンナビノイド製剤
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
WO2019234743A1 (en) * 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
JP2022534763A (ja) * 2019-05-31 2022-08-03 ジーダブリュー・リサーチ・リミテッド カンナビノイド製剤

Also Published As

Publication number Publication date
US20210205235A1 (en) 2021-07-08
US12186281B2 (en) 2025-01-07
US11717494B2 (en) 2023-08-08
BR112022010335A2 (pt) 2022-08-16
WO2021140183A1 (en) 2021-07-15
CA3164489A1 (en) 2021-07-15
US20230065736A1 (en) 2023-03-02
CN114845705A (zh) 2022-08-02
AU2021206021A1 (en) 2022-06-02
EP4087547A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP6105761B2 (ja) 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
JP6434429B2 (ja) デフェラシロクスの経口製剤
US20060127476A1 (en) Tranexamic acid formulations with reduced adverse effects
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US12186281B2 (en) Oral solid cannabinoid oil composition for treating gastrointestinal disorders
RU2738114C2 (ru) Пероральные фармацевтические композиции никотинамида
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
US20240050377A1 (en) Oral solid cannabinoid oil composition for treating central nervous system disorders
HK40005191A (en) Oral pharmaceutical compositions of nicotinamide
HK40005191B (en) Oral pharmaceutical compositions of nicotinamide
AU2015203894A1 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250415